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ARTICLE
Unraveling genetic predisposition to familial or early
onset gastric cancer using germline whole-exome
sequencing
Ingrid P Vogelaar1, Rachel S van der Post2, J Han JM van Krieken2, Liesbeth Spruijt1,
Wendy AG van Zelst-Stams1, C Marleen Kets1, Jan Lubinski3, Anna Jakubowska3, Urszula Teodorczyk3,
Cora M Aalfs4, Liselotte P van Hest5, Hugo Pinheiro6,7, Carla Oliveira6,7,8, Shalini N Jhangiani9,10,
Donna M Muzny9,10, Richard A Gibbs9,10, James R Lupski9,10, Joep de Ligt1, Lisenka ELM Vissers1,
Alexander Hoischen1, Christian Gilissen1, Maartje van de Vorst1, Jelle J Goeman11,12, Hans K Schackert13,
Guglielmina N Ranzani14, Valeria Molinaro14, Encarna B Gómez García15, Frederik J Hes16,
Elke Holinski-Feder17, Maurizio Genuardi18, Margreet GEM Ausems19, Rolf H Sijmons20, Anja Wagner21,
Lizet E van der Kolk22, Inga Bjørnevoll23, Hildegunn Høberg-Vetti24, Ad Geurts van Kessel1, Roland P Kuiper1,
Marjolijn JL Ligtenberg1,2,25 and Nicoline Hoogerbrugge*,1,25
Recognition of individuals with a genetic predisposition to gastric cancer (GC) enables preventive measures. However, the
underlying cause of genetic susceptibility to gastric cancer remains largely unexplained. We performed germline whole-exome
sequencing on leukocyte DNA of 54 patients from 53 families with genetically unexplained diffuse-type and intestinal-type GC to
identify novel GC-predisposing candidate genes. As young age at diagnosis and familial clustering are hallmarks of genetic tumor
susceptibility, we selected patients that were diagnosed below the age of 35, patients from families with two cases of GC at or
below age 60 and patients from families with three GC cases at or below age 70. All included individuals were tested negative
for germline CDH1 mutations before or during the study. Variants that were possibly deleterious according to in silico predictions
were ﬁltered using several independent approaches that were based on gene function and gene mutation burden in controls.
Despite a rigorous search, no obvious candidate GC predisposition genes were identiﬁed. This negative result stresses the
importance of future research studies in large, homogeneous cohorts.
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INTRODUCTION
Annually, almost one million people develop gastric cancer (GC) and
~ 723 000 people die of this disease worldwide.1 This makes GC the
ﬁfth most common malignancy and the third leading cause of cancer-
related mortality worldwide.1 In Western Europe, the incidence of
gastric cancer (GC) is 8.8 per 100 000 persons for men and 4.3 per
100 000 persons for women.1
GC is a multifactorial disease in which both genetic and environ-
mental factors are involved. The main environmental factor is
infection with Helicobacter pylori, which increases the risk of develop-
ing GC about six-fold.2 The World Health Organization (WHO)
classiﬁed H. pylori as a class I carcinogen in 1994.3,4
GC is a heterogeneous disease and can be roughly divided into three
main types; diffuse-type GC, intestinal-type GC and a remaining
group composed of mixed and indeterminate GC types.5 Diffuse-type
GC (DGC) consists of poorly cohesive single cells without gland
formation. Due to the frequent presence of signet ring cells, this type
of GC is often referred to as signet ring cell carcinoma. Intestinal-type
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GC (IGC) is composed of glandular or tubular components with
various degrees of differentiation.6
In both low and high GC incidence countries, around 8–30% of
patients with GC have a familial history of GC.7–11 Germline CDH1
pathogenic mutations, predisposing to hereditary diffuse gastric cancer
(HDGC), have been encountered in a subset of GC families.12–19 The
International Gastric Cancer Linkage Consortium has recently broa-
dened the CDH1 testing criteria with the aim to identify as many
CDH1 mutation carriers as possible.20
Families in whom no germline CDH1 mutation can be identiﬁed
remain genetically unexplained and may carry pathogenic mutations
in other, yet unknown, GC susceptibility genes. Recently, DGC
families with mutations in CTNNA116,21 and MAP3K622 have been
described, but the exact contribution of these genes to GC predis-
position remains unclear until more families with mutations in these
genes are reported. In families with IGC exhibiting an autosomal
dominant inheritance pattern, genetic susceptibility genes may also
play a role, but no genes have yet been associated with this type of GC.
The aim of the current study was to identify novel candidate GC
susceptibility genes using whole-exome sequencing of germline DNA
isolated from the blood of patients suspected of genetic predisposition
for GC, but without CDH1 mutations.
MATERIALS AND METHODS
Patient selection for exome sequencing
In our exome sequencing cohort, 54 patients from 53 families meeting one of
the following criteria were included: one gastric cancer diagnosed below the age
of 35 years, two GC cases diagnosed in ﬁrst- or second-degree relatives at or
below the age of 60 years (index diagnosed at or below the age of 50 years) or
three cases of GC in ﬁrst- or second-degree relatives diagnosed at or below 70
years of age. The majority of the patients (n= 33) had previously been proven
negative for CDH1 mutations. For each family a single patient was included,
with the exception of one family for which two patients were tested. Patient
characteristics are shown in Table 1. This study was approved by the medical
ethics committee of the Radboud university medical center, reference number
2013/201 and the Institutional Review Board of the Baylor College of Medicine.
Exome sequencing, variant annotation and exclusion of normal
variation
Detailed information on the sequencing statistics of individual samples can be
found in Supplementary Table 1 Online. Whole-exome sequencing of genomic
DNA extracted from peripheral blood cells of the patient was performed using
the 5500XL SOLiD platform (Life Technologies, Bleiswijk, The Netherlands) for
26 samples and on the Illumina HiSeq (2x100bp paired end; Illumina, Inc.,
San Diego, CA, USA) for 13 samples (BGI, Copenhagen, Denmark). Exome
enrichment was performed using either the human SureSelect All Exon 50 Mb
kit (n= 11) or the human SureSelect All Exon V4 kit (n= 28), targeting the
coding regions of ~ 21 000 human genes (Agilent Technologies, Santa Clara,
CA, USA). Reads were mapped to the Human Genome Reference Assembly
GRCh37/hg19 using LifeScope software (Life Technologies) for samples
sequenced on the SOLiD instrument and variants were called with the DiBayes
algorithm. Exomes that were sequenced on the Illumina instrument were
mapped using BWA and variants were called with GATK. All variants were
annotated using an in-house annotation pipeline, as described previously.23,24
For 15 patients, exome sequencing was performed through the Human
Genome Sequencing Center at Baylor College of Medicine, according to
previously described methods.25,26 Sequencing was performed on the Illumina
HiSeq 2000 platform (Illumina, Inc.). Subsequently, reads were mapped and
aligned to the Human Genome Reference Assembly GRCh37/hg19 using the
BCM-HGSC Mercury pipeline.27 Variant calling was performed with the
Atlas228 and SAMtools29 algorithms; variant annotation was performed with
an in-house developed annotation pipeline30 based on ANNOVAR.31 Custom
scripts were used incorporating multiple databases to retrieve more information
on identiﬁed variants.
From our total set of variants we selected high-conﬁdence (≥5 variant reads
or ≥ 20% variant reads) non-synonymous variants that were absent from
dbSNP or had a dbSNP (v132) frequency o1% and which occurred at most
once in our in-house variant database (2096 exomes, the majority of which are
from European ancestry).23
Enrichment of truncating variants compared to controls
The number of different truncating variants (nonsense variants, indels leading
to a frameshift and variants in canonical splice sites) per gene was established
for our data set and an independent in-house database containing 2329 exomes.
Also, the number of genes with a given number of variants was determined for
the combined datasets. The Fisher’s exact test (incorporated in the IBM SPSS
Statistics software package version 20, IBM Corporation, Armonk, NY, USA)
was used to determine whether the number of variants for a certain gene in our
set was enriched compared with the control data set. To correct for multiple
testing we used the modiﬁed Bonferroni procedure for discrete data32 based on
the number of genes with the same number of truncating mutations observed
in the gene of interest. All genes with a P-valueo0.05 after multiple testing
correction were included for further analysis.
Variant prioritization based on gene function
Missense variants with a PhyloP≥ 3 in selected pathways (see below) were
analyzed using the Alamut 2.0 software package (Interactive Biosoftware,
Rouen, France), which incorporates SIFT,33 PolyPhen-2,34 Align GVGD35
and dbSNP (build 135). Missense variants that were predicted deleterious/
damaging by at least two of these programs were considered possibly
deleterious. Data was analyzed using Alamut software between September
2013 and December 2014.
These possibly deleterious missense variants and the truncating variants were
prioritized based on gene function using the following criteria. The ﬁrst
criterion used included variants in known hereditary (gastric) cancer predis-
posing genes. For this analysis we used an in-house generated list of 113 genes
(Supplementary Table 2 Online). In addition, we assessed the recently described
GC-predisposing genes CTNNA116,21 and MAP3K622 for variants. Second, we
selected genes putatively involved in GC development. A gene list
(Supplementary Table 2 Online) for this category was composed by combining
a list of known tumor-suppressor genes36 with genes from the following KEGG
pathways:37 regulation of actin cytoskeleton (entry 04810), adherens junction
(entry 04520), focal adhesion (entry 04510), epithelial cell signaling in H. pylori
infection (entry 05120) and pathways in cancer (entry 05200). Third, based on
the detection of a homozygous putatively deleterious variant in MYD88 in one
of the patients of this cohort,38 we used the Resource of Asian Primary
ImmunoDeﬁciencies (RAPID) gene list,39 an in-house generated candidate gene
list and three KEGG pathways (JAK-STAT pathway (entry 04630), NFκB
pathway (entry 04064) and TLR pathway (entry 04620)37 to select variants
known to predispose to immunodeﬁciencies. As a fourth criterion, we selected
genes with a high expression in the stomach (based on data from the Tissue-
speciﬁc Gene Expression and Regulation (TiGER) database40). The combined
gene list for the categories mentioned above can be found in Supplementary
Table 2 Online.
The National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing
Project (ESP; 6503 exomes) database (hereafter referred to as EVS41), which
contains sequencing data of ~ 6500 individuals of European and African
descent was used to assess whether selected variants were present in individuals
selected for other diseases than cancer. Furthermore, we used a second in-house
database containing 2329 exomes with high coverage to exclude common
variants. Finally, the database from the Exome Aggregation Consorium (ExAc42)
was used to obtain the frequency of speciﬁc variants in a larger control
population.
For all truncating variants affecting genes not represented in the selected
pathways presented above, the possible relation of the affected gene with GC
tumorigenesis was evaluated based on the known function of the gene.
Variants described in this manuscript and Supplementary Tables Online
are submitted to the Leiden Open Variant Database (LOVD, ID numbers
103989–104041).
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Table 1 Patient characteristics exome sequencing cohort
Subject
(UPN)
Country of
inclusion
Age at
diagnosis
GC
Family
history
of GC Criteriuma
GC
histology
reviewed Lauren WHO
GC histology
original pathology
reports
Histology of
GC cases in
family
Other
remarks
005A The Nether-
lands
50 FDR DGC 50, FDR GC 48 3 Yes Diffuse Poorly
cohesive
Diffuse (poorly
cohesive)
DGC
018A The Nether-
lands
26 SDR GC 27, TDR GC 55 3 Yes Diffuse Poorly
cohesive
Diffuse (poorly
cohesive)
DGC
023A The Nether-
lands
43 FDR DGC 58 2 Yes Diffuse Poorly
cohesive
Diffuse (poorly
cohesive)
DGC
025A The Nether-
lands
32 No 1 Yes Diffuse Poorly
cohesive
Diffuse (poorly
cohesive)
DGC
036A The Nether-
lands
23 No 1 Yes Diffuse Poorly
cohesive
Diffuse (poorly
cohesive)
DGC Consanguineous
042A The Nether-
lands
35 FDR GC 50 2 No Diffuse (poorly
cohesive)
DGC
049A The Nether-
lands
66 FDR IGC 54, FDR GC 60, SDR
IGC 83, SDR GC 50, SDR GC
58, SDR GC 60
3 Yes Intestinal Tubular Intestinal
(tubular)
IGC
059A The Nether-
lands
35 FDR DGC 51, FDR GC 22, FDR
GC 42
3 Yes Diffuse Poorly
cohesive
Diffuse (poorly
cohesive)
DGC
059B The Nether-
lands
51 FDR DGC 35, FDR GC 22, FDR
GC 42
3 Yes Diffuse Poorly
cohesive
Diffuse (poorly
cohesive)
DGC
107A The Nether-
lands
69 FDR GC 57, FDR GC 66, FDR
GC 72, FDR GC 81
3 Yes Intestinal Tubular Not speciﬁed
‘adenocarcinoma’
IGC
112A The Nether-
lands
34 No 1 Yes Diffuse Poorly
cohesive
Diffuse (poorly
cohesive)
DGC
119A The Nether-
lands
31 No 1 Yes Intestinal Tubular Intestinal
(tubular)
IGC
120A The Nether-
lands
31 No 1 Yes Intestinal Tubular Not speciﬁed
‘adenocarcinoma’
IGC Consanguineous
121A The Nether-
lands
27 No 1 No Diffuse (poorly
cohesive)
DGC
124A The Nether-
lands
54 FRD IGC 51, FDR IGC 53, TDR
IGC 55, TDR GC 35
3 Yes Intestinal Mucinous Intestinal
(mucinous)
IGC
125A The Nether-
lands
33 FDR DGC 56 2 No Diffuse (poorly
cohesive)
DGC
135A The Nether-
lands
46 FDR GC 52 2 Yes Diffuse Poorly
cohesive
Diffuse (poorly
cohesive)
DGC Patient also had ductal
breast carcinoma at age
51
162A The Nether-
lands
33 FDR IGC 42 2 Yes Diffuse Poorly
cohesive
Diffuse (poorly
cohesive)
Combined
DGC and
IGC
164A The Nether-
lands
36 No 1 Yes Diffuse Poorly
cohesive
Not speciﬁed
‘adenocarcinoma’
DGC
167A The Nether-
lands
31 No 1 Yes Diffuse Poorly
cohesive
Diffuse (poorly
cohesive)
DGC
509A Portugal 49 FDR GC, SDR GC, SDR GC 3 No Diffuse (poorly
cohesive)
DGC
510A Portugal 41 FDR DGC 21, FDR DGC 40 3 No Diffuse (poorly
cohesive)
DGC
511A Portugal 34 SDR DGC 54 2 No Diffuse (poorly
cohesive)
DGC
512A Portugal 48 FDR DGC, SDR DGC 3 No Diffuse (poorly
cohesive)
DGC
513A Portugal 30 Familial history of DGC,
incomplete information
1 No Diffuse (poorly
cohesive)
DGC
516A Germany 29 No 1 No Diffuse (poorly
cohesive)
DGC
520A Germany 28 No 1 No Diffuse (poorly
cohesive)
DGC
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Table 1 (Continued)
Subject
(UPN)
Country of
inclusion
Age at
diagnosis
GC
Family
history
of GC Criteriuma
GC
histology
reviewed Lauren WHO
GC histology
original pathology
reports
Histology of
GC cases in
family
Other
remarks
521A Germany 43 FDR GC 47 2 No Intestinal
(tubular)
IGC
522A Germany 23 No 1 No Not speciﬁed
‘adenocarcinoma’
AC
529A Italy 34 SDR GC 41 2 No Not speciﬁed
‘adenocarcinoma’
AC
530A Italy 30 No 1 No Not speciﬁed
‘adenocarcinoma’
AC
531A Italy 34 No 1 No Diffuse (poorly
cohesive)
DGC Patient also had basal
cell carcinoma at age
42 and DGC 53
532A Italy 30 No 1 No Not speciﬁed
‘adenocarcinoma’
AC
701A Poland 22 No 1 No Diffuse (poorly
cohesive)
DGC
703A Poland 68 FDR GC 42, FDR GC 65 3 No Not speciﬁed
‘adenocarcinoma’
AC
711A Poland 49 FDR GC 46 2 No Intestinal
(mucinous)
IGC
716A Poland 45 FDR GC 50 2 No Intestinal
(tubular)
IGC
725A Poland 38 FDR GC 50, SDR GC 56 3 No Not speciﬁed
‘adenocarcinoma’
AC
727A Poland 42 FDR GC 50, SDR GC 56 3 No Not speciﬁed
‘adenocarcinoma’
AC
729A Poland 48 FDR GC 40, FDR GC 79 3 No Intestinal
(tubular)
IGC Patient also had liver
cancer age 50
730A Poland 29 SDR GC 35 2 No Intestinal
(tubular)
IGC
731A Poland 28 No 1 No Not speciﬁed
‘adenocarcinoma’
AC
733A Poland 70 FDR GC 52, FDR GC 62 3 No Not speciﬁed
‘adenocarcinoma’
AC
741A Poland 29 No 1 No Diffuse (poorly
cohesive)
DGC
743A Poland 25 FDR GC 49 2 No Not speciﬁed
‘adenocarcinoma’
AC
755A Poland 30 No 1 No Not speciﬁed
‘adenocarcinoma’
AC
756A Poland 50 FDR GC 48 2 No Mixed Mixed
759A Poland 25 No 1 No Diffuse (poorly
cohesive)
DGC
760A Poland 30 FDR GC 70, SDR GCo75,
SDR GCo75
1 No Not speciﬁed
‘adenocarcinoma’
AC
762A Poland 32 FDR GC 46 2 No Not speciﬁed
‘adenocarcinoma’
AC
763A Poland 45 FDR GC 40 2 No Not speciﬁed
‘adenocarcinoma’
AC
772A Poland 34 No 1 No Not speciﬁed
‘adenocarcinoma’
AC
774A Poland 33 No 1 No Diffuse (poorly
cohesive)
DGC
780A Poland 36 FDR GC 39 2 No Diffuse (poorly
cohesive)
DGC
Abbreviations: AC, adenocarcinoma not speciﬁed; DGC, diffuse-type gastric cancer; FDR, ﬁrst-degree relative; IGC, intestinal-type gastric cancer; SDR, second-degree relative; TDR, third-degree
relative.
aOne gastric cancer diagnosed below the age of 35 years, two GC cases diagnosed in ﬁrst- or second-degree relatives at or below the age of 60 years (index diagnosed at or below the age of 50
years) or three cases of GC in ﬁrst- or second-degree relatives of GC diagnosed at or below 70 years of age.
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Validation of variants and CDH1 exon 1 germline mutation
analysis by Sanger sequencing
The DNA sequence surrounding the variant was ampliﬁed using polymerase
chain reaction (PCR, primer sequences and PCR conditions are available on
request) and screened for mutations using BigDye terminator sequencing
(BigDye Terminators (v 1.1) Applied Biosystems, Foster City, CA, USA).
Analysis was performed on an ABI 3730 DNA Analyzer (Applied Biosystems).
Subsequently, the data were analyzed using Vector NTI advance v11.0
(Invitrogen Corporations, Paisley, UK) or Chromas Lite (Technelysium,
Australia). For mutation analysis of CDH1 exon 1 in a subset of the patients,
primers surrounding the intron-exon boundaries of this exon were used. PCR
and sequencing was performed as described for variant validation.
RESULTS
Patient cohort and characteristics
Whole-exome sequencing was performed on germline DNA from 54
patients of 53 families. In this cohort 23 patients below the age of 35
were included (two without a family history of GC), 16 patients had
two cases of GC in the family at or below the age of 60 and 15 patients
were from families with three or more GC cases at or below 70 years
of age; in this group two patients from one family were included. The
mean age at diagnosis of all patients included was 37.9 years (SD 11.9,
range 22–70).
According to the original pathology reports, 27 patients had DGC, 8
patients had IGC, one GC was mixed-type and 18 tumors were
‘adenocarcinoma not otherwise speciﬁed’. For 17 cases, we were able
to review and conﬁrm the histology of the GC (12 patients with DGC
and ﬁve with IGC). For the remaining cases no revision could be
performed.
Exome sequencing statistics
Three different enrichment kits and two different sequencing plat-
forms were used for exome sequencing. On average, 5.2 Gb of data
aligned to targets was generated per sample (range: 2–10.2 Gb), hitting
98.9% of the targets (96–99.98%) with an average coverage of 81.7×
(36.8–132× ). A coverage of at least 10-fold was reached for 93.3% of
the targets (81.1–99.31%) and 87.7% was covered at least 20-fold
(68.9–98.19%). The statistics for individual exome sequencing data
can be found in Supplementary Table 1 Online. Approximately 9200
variants from 54 cases remained (average 170, range 87–379). To test
our quality settings, we performed Sanger sequencing on a subset of
these variants and found that we were able to conﬁrm 93% of the
variants.
Variants in previously described gastric cancer predisposition genes
None of the cases carried pathogenic mutations in CDH1. Also, no
variants were found in CTNNA1, which has recently been described as
GC-predisposing gene.16,21 Three variants were identiﬁed in MAP3K6;
two missense variants (p.Y591C and p.L541P) and one amino acid
deletion (p.K1125del). MAP3K6 has been associated with familial
GC.22 However, based on the high number ofMAP3K6 variants found
in non-cancerous controls, we did not follow-up on these variants.
Enrichment of truncating variants compared with controls
As the deleterious effect of truncating variants (nonsense variants,
indels leading to a frameshift and variants in canonical splice sites) is
most prominent, we tested whether the recurrence of truncating
mutations in a given gene was different from that in a control exome
sequence data set of 2329 individuals. In our data set, in 12 genes two
different truncating variants occurred (Supplementary Table 3
Online). After correction for multiple testing, no enrichment of
truncating variants was found in these genes compared to the control
cohort.
Occurrence of homozygous or compound heterozygous variants
To explore the occurrence of pathogenic changes in GC predisposition
genes that follow a recessive inheritance pattern, we explored whether
missense and/or truncating variants occurred in a homozygous or
compound heterozygous form in our set of patients with an age at
diagnosis below 35. Apart from a germline homozygous missense
variant in MYD88 in a patient with GC at age 23 and recurrent
candidiasis, which we previously published,38 no other candidate genes
were found.
Variant prioritization based on gene function
Because of the large amount of missense and truncating variants,
prioritization was performed based on the function and recurrence of
the affected genes. To select variants that may be involved in GC
predisposition, we created a gene list composed of 1899 genes (for
details see Materials and Methods and Supplementary Table 2 Online).
Our exome data were then ﬁltered for variants in these genes. After in
silico prediction, 252 possibly deleterious variants were identiﬁed using
this approach (on average 5 per patient, range 1–11). The number of
variants in the individual pathways and databases can be found in
Table 2, variant details are shown in Supplementary Table 4 Online
(excluding variants that were not conﬁrmed after validation using
Sanger sequencing). Twenty-one variants were identiﬁed in known
cancer predisposing genes (Table 2; Supplementary Table 4 Online),
including four different heterozygous variants (two truncating and two
missense) in the ATM gene, previously associated with a small
increased GC risk (RR= 3.39, 95% CI= 0.86 to 13.4).43 No obvious
candidate GC predisposition genes were identiﬁed from either the
hereditary cancer list, or the other pathways we selected. In addition,
for all truncating variants affecting genes not represented in the
selected pathways, the putative relation with GC tumorigenesis of the
affected gene was evaluated based on the known function of the gene.
This did not result in a convincing candidate gene.
Table 2 Number of potential deleterious variant calls in different
pathways
Pathway/gene list (number of genes in pathway)
Total number of
variants
KEGG Actin cytoskeleton (151)a 17
KEGG Adherens junction (73)a 20
KEGG Focal adhesion (205)a 43
KEGG Helicobacter pylori (68)a 4
KEGG JAK-STAT pathway (158)a 3
KEGG NFkB signaling (92)a 12
KEGG TLR pathway (106)a 7
KEGG Pathways in cancer (327)a 48
TiGER database (207)b 16
Asian Primary ImmunoDeﬁciencies (247)c 38
In-house generated gene list of genes predisposing to
immunodeﬁciencies (271)
37
In-house generated gene list of genes predisposing to
hereditary cancer (113)
21
Human TSGene (716)d 107
aSee reference.37
bSee Liu et al.40
cSee Keerthikumar et al.39
dSee Zhao et al.36
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DISCUSSION
In the current study, whole-exome sequencing was performed on
germline DNA from 54 GC patients from 53 families with the aim to
identify novel GC susceptibility genes. In order to increase the
likelihood of ﬁnding a putative causative mutation underlying GC,
these patients were selected from families at high risk of a genetic
predisposition, who met strict inclusion criteria. No clear novel GC
predisposition gene was identiﬁed.
Mutations in CDH1 were not detected in the 21 cases for which no
CDH1 mutation analysis had been performed prior to our study. In
two recent studies, germline mutations in CTNNA1 were identiﬁed in
families with GC.16,21 This gene is in the same pathway as E-cadherin,
making it a plausible GC predisposition gene. In our data set of 54
patients no mutations in CTNNA1 were found, which indicates that
mutations in this gene probably do not explain a large proportion of
the early onset gastric or familial cancer in patients that tested negative
for germline CDH1 mutations.
Gaston et al. reported on variants in the MAP3K6 gene in familial
GC.22 We have also observed variants in this gene, but we do not
consider this gene a strong GC candidate gene for two reasons. Firstly,
in the study by Gaston et al. the gene variant p.P946L was identiﬁed in
a large family, but the variant does not completely segregate with the
disease.22 Secondly, this variant occurs quite frequently in the ExAc
database (n= 640/0.5% allele frequency). This argues against its
pathogenicity, simply because it is not expected that a variant that
occurs so frequently in a database containing exomes of people
without suspicion of hereditary cancer would cause GC, a relatively
rare form of hereditary cancer.
The observation that frequently occurring variants are reported as
candidate genes for GC development stresses the importance to
determine the frequency of variants in candidate genes in local and
public control datasets in addition to assessment of functional
relevance. In the current study, we have used three datasets to
compare our exome data with. The ﬁrst one is an independent in-
house database containing 2329 exomes sequenced with high coverage.
The second one is the EVS database,41 which contains sequencing data
of ~ 6500 individuals of European and African descent. The third is
the ExAc database,42 containing exome data of 60 706 unrelated
individuals. These datasets allowed for more stringent ﬁltering of
the data.
Even though we identiﬁed over 9200 rare variants in these 54
patients, we were unable to unequivocally show that among these are
the disease-causing variants and, therefore, GC-predisposing genes.
There may be several reasons for the fact that we did not ﬁnd clear
candidate genes in the current study. For example, the large amount of
variants in our data set may have inﬂuenced our ability to recognize
candidate genes as such. Additionally, a gene similar to the previously
described CTNNA1mutations (which account for only a small portion
of GC families) may well have remained undetected in our data set.
Furthermore, our strictly selected patient cohort might be too small to
identify candidate genes, especially to determine enrichment of genes
or pathways compared to controls. Another reason is that, even
though we used strict criteria for the selection of families, the patient
group that we included in this study is still quite heterogeneous. We
included patients with both DGC and IGC, who were either diagnosed
at young age or had a family history of GC. For a number of cases the
histological subtype was unknown, underscoring the importance of
extensive pathological review and reporting of GC according to
current guidelines.20 It may be very well possible that performing
whole-exome sequencing in a more homogeneous patient cohort may
allow for improved detection of candidate genes, although other
studies also did not identify promising new GC predisposition
genes.16,44,45 Also, we performed exome sequencing, whereas predis-
posing variants may also be in non-protein coding parts of the
genome, currently not analyzed. Since we collected only one family
member for each family and affected family members are often
deceased due to the cancer, we were not able to follow-up on potential
candidate genes. Finally, it could be possible that some of the patients
we included developed cancer because of chance and occasional
familial clustering or complex inheritance involving multiple genomic
alterations.
Future perspectives
Taken together, we performed exome sequencing in 54 CDH1
mutation-negative patients from 53 families. In this study we did
not identify obvious candidate genes for GC predisposition. Future
studies should be performed in larger, homogeneous patient groups
and we would suggest that data from different research groups should
be combined to identify candidate genes in these families. If candidate
genes are identiﬁed this way, it will enable better preventive care in
carriers of these mutations.
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